at Investor's Business Daily (Jan 8, 2015)
Shares of NuVasive (NUVA -0.9%) aren't getting much help today from upgrade to Outperform at...
Shares of NuVasive (NUVA -0.9%) aren't getting much help today from upgrade to Outperform at Wells Fargo as the stock struggles to break through key technical resistance levels. Wells cites improvements in the spine market and the company's conservative 2012 guidance for the upgrade. The firm alos raised its price target range to $29 - $31 from $17 - $18.
From other sites
at Zacks.com (Nov 14, 2014)
at Zacks.com (Nov 5, 2014)
at MarketWatch.com (Oct 4, 2012)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs